The First Solid-State 308/311nm Ti:Sapphire UVB Laser
PALLAS is the world’s first UVB laser with highly safe and efficacious wavelengths with a therapeutic beam for treating a variety of complex skin conditions such as vitiligo, psoriasis, atopic dermatitis and leukodermas.
World First Solid-State Ti:Sapphire UVB Laser
Vitiligo 100% Re-Pigmentation
No Ongoing Costs / High ROI
Understanding Vitiligo and Psoriasis
Vitiligo is a relatively common depigmentation disorder that negatively impacts approximately 1% of the world population or 70 million people. This disorder affects demographics of all ages, genders, backgrounds, and of these affected patients 20-35% are adolescents.
Psoriasis is a common skin condition that speeds up the life cycle of skin cells and is an immune-mediated genetically determined common dermatological disorder which affects skin, nails, joints and has various systemic associations.
The prevalence of psoriasis by country varies between 0.09% and 11.4% of the population. It is a serious global problem affecting 125 million people worldwide across all age groups.
Why is the PALLAS Unique?
LASEROPTEK invested the last decade researching, developing, and designing PALLAS, the world’s first and only Ti:Sapphire based solid-state UVB laser available. Utilizing LASEROPTEK’s unique and proprietary harmonic generation technology, PALLAS converts the Ti:Sapphire’s 933nm output to 311nm, a highly safe and efficacious wavelength for treating a variety of complex skin conditions.
PALLAS exhibits world-leading conversion efficiency and this technology and achievement is featured in the 2015 publication of “Optics Letters.”
It is a well-known and studied fact that the 310-313nm wavelength range (narrowband UVB) is the most effective in treating complex skin conditions such as vitiligo and psoriasis while avoiding the burning effects common with shorter wavelengths such as the 308nm.
Through careful consideration and consistent testing, LASEROPTEK chose the 311nm wavelength due to its ability to penetrate deeper into the skin in comparison with a 308nm Excimer Laser in order to stimulate more melanocytes around hair follicles.
Proven Efficacy and Safety
PALLAS is clinically proven to provide significant and long-lasting relief in fewer treatments in comparison with topical and other phototherapies. It can effectively treat anatomical locations that are challenging to treat while being painless and having long-lasting effects.
PALLAS shows an overall 100% re-pigmentation rate when treating vitiligo, 79% excellent to complete re-pigmentation, and 21% good or moderate re-pigmentation. The initial response is fast, and re-pigmentation begins from as little as the 4th and at latest the 9th treatment sessions. The therapeutic mechanism of TSL involves immune modulation and melanocyte stimulation, as found in narrowband UVB and EL treatment.
No Ongoing Costs / High ROI
PALLAS solid-state design eliminates the need to replace expensive consumables, thereby significantly lowering the cost of operation and ownership in addition to service downtime throughout the laser’s operational lifetime.
PALLAS allows physicians to simply focus on treating patients.
- A review of the worldwide prevalence of vitiligo in children/adolescents and adults, Christian Kruger and Karin Uta Schallreuter. International Journal of Dermatology
- Global Vitiligo Foundation
- IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)
- The Efficacy of a Gain-Switched 311-nm Titanium:Sapphire Laser in the Treatment of Vitiligo: A Pilot Study of 14 Patients, Bae Jung Min, et al. JAMA Dermatol. 2017 Oct 1;153(10):1055-1056